Accenture plc vs Boston Scientific Corporation — how do they compare? Accenture plc trades at $178.96 (market cap $110.04B), while Boston Scientific Corporation trades at $51.05 (market cap $74.19B). The key difference: Accenture plc is the larger of the two by market cap, and Accenture plc pays a 3.63% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ACN | BSX | |
|---|---|---|
Market Cap | $110.04B | $74.19B |
Sector | Technology | Health |
52-Week High | $288.54 | $108.14 |
52-Week Low | $124.41 | $42.63 |
Enterprise Value | $108.26B | $86.27B |
Dividend Yield | 3.63% | — |
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $179.82, up 2.33% in the last session, with a bullish technical outlook and strong fundamental performance. The stock exhibits robust revenue growth, with 2025 revenue reaching $69.67 billion and net income of $7.68 billion, supported by consistent earnings beats. Recent partnerships with TEPCO Solution Advance and AlphaSense highlight strategic AI initiatives, enhancing its consulting and digital transformation services.
The investment outlook is positive, driven by solid financials, a consensus price target of $189.77, and low debt. Risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is strongly bullish with 66% buy ratings, indicating confidence in continued growth and shareholder value creation.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →